← United States · Coverage record
US · SEC FORM 4
Viking Therapeutics, Inc.
VKTX · Nasdaq · CIK 0001607678 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
7 Form 4 transaction lines observed in the same window
3 sales · 4 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-03-10 · Aubuchon Neil William.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 25,921,759
- Previous report
- 22,583,758
- Avg daily volume
- 12,010,250
- Days to cover
- 2.2
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-03-10 | Aubuchon Neil William | Purchase (P) | Common Stock, par value $0.00001 per share | 4,475 | USD 33.50 | USD 149,912 | SEC filing ↗ |
| 2025-03-31 | Rouan Sarah Kathryn | Purchase (P) | Common Stock, par value $0.00001 per share | 1,240 | USD 24.15 | USD 29,946 | SEC filing ↗ |
| 2025-03-31 | Rouan Sarah Kathryn | Purchase (P) | Common Stock, par value $0.00001 per share | 1,240 | USD 24.15 | USD 29,946 | SEC filing ↗ |
| 2022-05-02 | FOEHR MATTHEW W | Purchase (P) | Common Stock, par value $0.00001 per share | 45,000 | USD 2.47 | USD 111,150 | SEC filing ↗ |
| 2021-06-10 | FOEHR MATTHEW W | Purchase (P) | Common Stock, par value $0.00001 per share | 20,000 | USD 5.69 | USD 113,800 | SEC filing ↗ |
Form 4 evidence
43 transaction lines in the latest 365-day window; 307 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-08-01 | Kelly-Gemmell Dorothy Elizabeth | Award / grant (A) | Common Stock, par value $0.00001 per share | 6,333 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-07-29 | ZANTE GREG | Sale (S) | Common Stock, par value $0.00001 per share | 21,217 | USD 33.47 | USD 710,133 | SEC filing ↗ |
| 2026-07-29 | Mancini Marianna | Sale (S) | Common Stock, par value $0.00001 per share | 18,217 | USD 33.47 | USD 609,723 | SEC filing ↗ |
Show recent Form 4 evidence (29 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-08-01 | Kelly-Gemmell Dorothy Elizabeth | Award / grant (A) | Common Stock, par value $0.00001 per share | 6,333 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-07-29 | ZANTE GREG | Sale (S) | Common Stock, par value $0.00001 per share | 21,217 | USD 33.47 | USD 710,133 | SEC filing ↗ |
| 2026-07-29 | Mancini Marianna | Sale (S) | Common Stock, par value $0.00001 per share | 18,217 | USD 33.47 | USD 609,723 | SEC filing ↗ |
| 2026-07-29 | Lian Brian | Sale (S) | Common Stock, par value $0.00001 per share | 148,517 | USD 33.32 | USD 4,948,586 | SEC filing ↗ |
| 2026-07-28 | ZANTE GREG | Award / grant (A) | Common Stock, par value $0.00001 per share | 31,667 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-07-28 | Mancini Marianna | Award / grant (A) | Common Stock, par value $0.00001 per share | 31,667 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-07-28 | Lian Brian | Award / grant (A) | Common Stock, par value $0.00001 per share | 221,667 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-03-10 | Aubuchon Neil William | Purchase (P) | Common Stock, par value $0.00001 per share | 4,475 | USD 33.50 | USD 149,912 | SEC filing ↗ |
| 2026-01-05 | ZANTE GREG | Sale (S) | Common Stock, par value $0.00001 per share | 57,661 | USD 32.90 | USD 1,897,129 | SEC filing ↗ |
| 2026-01-05 | Mancini Marianna | Sale (S) | Common Stock, par value $0.00001 per share | 57,661 | USD 32.97 | USD 1,901,275 | SEC filing ↗ |
| 2026-01-05 | Lian Brian | Sale (S) | Common Stock, par value $0.00001 per share | 233,409 | USD 32.96 | USD 7,692,305 | SEC filing ↗ |
| 2026-01-02 | ZANTE GREG | Award / grant (A) | Common Stock, par value $0.00001 per share | 73,049 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-02 | SINGLETON J MATTHEW | Award / grant (A) | Common Stock, par value $0.00001 per share | 3,150 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-02 | Rowland Charles A Jr | Award / grant (A) | Common Stock, par value $0.00001 per share | 3,150 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-02 | Rouan Sarah Kathryn | Award / grant (A) | Common Stock, par value $0.00001 per share | 3,150 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-02 | Mancini Marianna | Award / grant (A) | Common Stock, par value $0.00001 per share | 73,049 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-02 | MACARTNEY LAWSON | Award / grant (A) | Common Stock, par value $0.00001 per share | 3,150 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-02 | Lian Brian | Award / grant (A) | Common Stock, par value $0.00001 per share | 302,480 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-02 | FOEHR MATTHEW W | Sale (S) | Common Stock, par value $0.00001 per share | 16,000 | USD 35.11 | USD 561,760 | SEC filing ↗ |
| 2026-01-02 | FOEHR MATTHEW W | Option exercise / conversion (M) | Common Stock, par value $0.00001 per share | 16,000 | USD 3.33 | USD 53,280 | SEC filing ↗ |
| 2026-01-02 | FOEHR MATTHEW W | Award / grant (A) | Common Stock, par value $0.00001 per share | 3,150 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-10-28 | ZANTE GREG | Sale (S) | Common Stock, par value $0.00001 per share | 6,185 | USD 35.00 | USD 216,475 | SEC filing ↗ |
| 2025-10-28 | Mancini Marianna | Sale (S) | Common Stock, par value $0.00001 per share | 6,185 | USD 35.00 | USD 216,475 | SEC filing ↗ |
| 2025-10-28 | Lian Brian | Sale (S) | Common Stock, par value $0.00001 per share | 38,989 | USD 35.01 | USD 1,365,005 | SEC filing ↗ |
| 2025-10-27 | ZANTE GREG | Award / grant (A) | Common Stock, par value $0.00001 per share | 11,117 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-10-27 | Rowland Charles A Jr | Sale (S) | Common Stock, par value $0.00001 per share | 60,000 | USD 35.57 | USD 2,134,200 | SEC filing ↗ |
| 2025-10-27 | Rowland Charles A Jr | Award / grant (A) | Common Stock, par value $0.00001 per share | 60,000 | USD 5.11 | USD 306,640 | SEC filing ↗ |
| 2025-10-27 | Mancini Marianna | Award / grant (A) | Common Stock, par value $0.00001 per share | 11,117 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-10-27 | Lian Brian | Award / grant (A) | Common Stock, par value $0.00001 per share | 70,084 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | VKTX |
| CIK | 0001607678 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 307 transaction lines from 2020-01-03 to 2026-08-01 5 P purchase lines · 110 S sale lines · 192 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.